Minerva Neurosciences 2024年第四季度GAAP每股收益$(0.56)优于预期的$(1.05),截至2024年12月31日现金、现金等价物和受限制现金约为$21.5M

财报速递
25 Feb
Minerva Neurosciences (NASDAQ:NERV)报告季度亏损每股$(0.56),优于分析师一致预期的每股亏损$(1.05),超出达46.67%。相比去年同期每股亏损$(1.19),这是增长了52.94%。

以上内容来自Benzinga Earnings专栏,原文如下:

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(1.05) by 46.67 percent. This is a 52.94 percent increase over losses of $(1.19) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10